Oncology & Cancer

New nanotechnology application for difficult-to-treat cancers

A new treatment combining shock waves with nanoparticles can successfully treat tumours that are difficult to target using conventional chemotherapy. This is the first time this combined therapy has been tested in live animals. ...

Oncology & Cancer

Long-term cardiomyopathy risk varies by chemo agent

(HealthDay)—Long-term cardiomyopathy risk varies by chemotherapy agent for childhood cancer survivors, with a decreased risk for daunorubicin versus doxorubicin, according to a study recently published in JAMA Oncology.

Oncology & Cancer

Taxane-induced neuropathy not tied to breast cancer outcome

(HealthDay) -- For patients with operable breast cancer, peripheral neuropathy due to adjuvant taxane therapy does not correlate with improved outcomes, according to research published online July 30 in the Journal of Clinical ...

Medications

First generic version of cancer drug Doxil approved

(HealthDay)—The first generic version of the cancer drug Doxil (doxorubicin hydrochloride liposome injection) has been approved by the U.S. Food and Drug Administration, which says the action should help relieve shortages ...

page 3 from 6